Intellectual Disabilities (F70-F79)EPRIDNCT06894264
Emotion Processing and Regulation in People With Intellectual Disability
A study testing Emotion regulation in people with Intellectual Disabilities (F70-F79) and Autism Spectrum Disorder, run by Karolinska Institutet.
Trial summary
BACKGROUND Intellectual disability (ID) is neurodevelopmental disorder with social impairments, in areas such as interpersonal communication skills and emotion regulation. This overlaps with disabilities associated with autism spectrum disorder (ASD). Read more about this study
- Who is it for?
- Ages 18 to 45 years
- Conditions the study is for
- Intellectual Disabilities (F70-F79), Autism Spectrum Disorder
- What is being tested?
- Emotion regulation
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- No sites listed yet
- Study dates
- 15 Aug 2026to 30 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Clinically diagnosed with mild ID based on DSM-5 criteria, corresponding to a general IQ between 52-70.
- Can read and communicate in Swedish.
Who cannot join
- Presence of severe sensory impairments (e.g., blindness, deafness)
- Current psychosis or affective disorder; significant neurologic disorders (e.g., epilepsy) or degenerative disorder (e.g.., dementia, Parkinson's disease)
- Ongoing substance abuse
- Specific medication that enhance cognitive performance (central stimulants) or psychotropic medication that could affect task performance (anti-epileptic medication)
- Emotion regulation therapy or corresponding psychotherapy last 12 months.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
BACKGROUND
Intellectual disability (ID) is neurodevelopmental disorder with social impairments, in areas such as interpersonal communication skills and emotion regulation. This overlaps with disabilities associated with autism spectrum disorder (ASD). Differences in emotion processing, specifically emotion recognition, reappraisal, and reinforcement learning, has not been compared between patients with ID and ASD. Despite difficulties in emotion regulation among patients with ID, there is a lack of adapted psychotherapy for this patient group.
Read more
AIMS
- To examine differences in emotion processing in individuals with intellectual disability (ID) compared to individuals with autism spectrum disorder (ASD) and typically developed individuals.
- To evaluate the feasibility and effectiveness of an adapted psychotherapeutic intervention to improve emotion regulation in individuals with ID.
Data and method
The first research question is addressed through a cross-sectional study involving 160 participants: 40 individuals with ID, 40 individuals with ASD, and 80 typically developed controls. Participants will undergo psychological experiments where the investigator simultaneously measure eye movement and pupil dilation using an eye-tracker. To investigate different aspects of social cognition, the investigator will use three psychological experiments: emotion recognition, emotion reappraisal, and reinforced learning in a social context. Differences in social cognition are subsequently used in predictive models to predict the group affiliation of study participants.
To evaluate the effectiveness and feasibility of an adapted emotion regulation treatment based on Dialectic Behavioral Therapy skills system (DBT-SS), the 40 study participants with ID will undergo a manual-based psychotherapy. The treatment consists of 24 group and individual sessions over 24 weeks. The treatment includes nine skill-systems. Outcome measures are administered at baseline, post-treatment, and at a 6-month follow-up.
SOCIETAL RELENVANCE
This research addresses a significant knowledge gap in social cognition and mental health in individuals with ID. The results may lead to a better understanding of differences in social cognition compared to individuals with ASD, and effective, targeted interventions for emotion regulation in individuals with ID. In the long run, the treatment could help reduce off-label prescription of antipsychotics to manage behavioral deviations in individuals with ID, as challenging behaviors often stem from difficulties with emotion regulation.
PROJECT REALISATION
The research group consists of an interdisciplinary composition of experts in neuropsychology, experimental psychology, and implementation of psychotherapeutic research. The project has obtained ethical approval and follows the principles of open science, with pre-registration of study protocols.
Read the detailed description
BACKGROUND
Individuals with intellectual disability (ID) experience significant difficulties in interpreting, controlling, and expressing emotions. These deficits in emotion processing contribute to challenging behaviors, manifesting as aggressive outbursts, self-injurious behaviors, or withdrawal. The ability to understand and regulate emotions plays a vital role in daily functioning and social interactions. Impairment in emotion regulation also leads to increased stress, anxiety, and mood disorders, further exacerbating behavioral issues and negatively impacting the overall quality of life for individuals with ID.
Traditional cognitive tests (e.g., Wechsler Adult Intelligence Scale, WAIS) are reliable in measuring certain cognitive abilities but fall short in assessing emotional processes and social learning under uncertainty. New, objective measurement tools grounded in cognitive and neuroscience theories, would enhance our understanding of the challenges that patients with ID face in a social context.
Study has shown that Patients with ID have greater difficulty recognizing emotions compared to typically developing peers. Patients with ASD share the same functional impairment. However, the underlying mechanisms for these difficulties may differ between the two groups. For individuals with ASD, reduced fixation on the eye region has been proposed as a contributing factor to their emotion recognition difficulties, while the difficulties for individuals with ID may be due to more complex cognitive factors beyond simply reduced eye fixation.
Emotional reappraisal is a cognitive strategy used to regulate emotions by reinterpreting the meaning of emotional stimuli. It is crucial for effective emotion regulation as it allows individuals to change their emotional responses by altering their perspective on the emotional situations. For individuals with ID, the cognitive demands of reappraisal may be challenging due to limitations in executive functioning and abstract thinking, whereas for ASD, difficulties in theory of mind could impede the ability to reframe emotional situations effectively. Elucidating the exact impairment in emotion reappraisal could therefore impact assessment tools, treatment strategy and response to emotion regulation therapy.
Research in psychology and neuroscience has identified feedback learning as a crucial form of learning in humans. Typically, people adhere to a simple, yet powerful and flexible strategy called reinforcement learning (RL). Central to RL is that learning is driven by a mismatch between the initial belief about the outcome and the actual outcome. This mismatch is known as a prediction error. Differences in how prediction errors are computed and used for learning could be a distinct feature in cognitive processing between patients with ID and ASD. Moreover, understanding prediction errors and reinforcement learning mechanisms from a social context may be crucial in explaining how individuals assimilate and respond to clinical interventions, potentially offering insights into treatment efficacy and personalized therapeutic approaches.
Prevalence of challenging behavior in individuals with ID is between 10-15% and a common reason for refferal to psychiatry. 65% of youths with intellectual and developmental disabilities who were referred to a mental health service were prescribed antipsychotics. However, randomized controlled trials have not demonstrated consistent efficacy for this approach (SMD=-0.85; 95% CI=-1.69 to -0.01; p=0.05). Despite the clear need for psychological interventions to adress this issue, there is a striking disparity in the availability and application of psychotherapy for individuals with ID compared to the general population. This gap in treatment options highlights the necessity for targeted interventions that enhance emotion regulation and social functioning in this population. Among the various therapeutic approaches, skills-based training programs rooted in Dialectical Behavior Therapy (DBT) have shown promise in addressing these challenges. DBT focuses on teaching skills in mindfulness, distress tolerance, emotion regulation, and interpersonal effectiveness. In a pilot study with six participants, this form of treatment led to decreased challenging behaviors, improved global functioning, and reduced hospital admissions, suggesting potential efficacy of this treatment approach in a Swedish context. However, existing studies have typically involved small numbers of participants, highlighting the need for further research to elucidate the efficacy and feasibility of emotion regulation therapy for patients with ID. Despite these limitations, DBT-SS represents a promising avenue for improving the quality of life and social functioning of individuals with intellectual disabilities.
Preliminary results
Associate Professor Kleberg's research group has extensive experience conducting eye-tracking studies in individuals with Autism Spectrum Disorder (ASD) and rare genetic syndromes across varying cognitive abilities. Their previous research has revealed distinct eye-movement patterns and pupillary responses in individuals with rare genetic syndromes, such as Williams syndrome and Turner syndrome, which differ from those observed in individuals with ASD during psychological experiments. This line of research is crucial for understanding the unique cognitive and social profiles associated with different neurodevelopmental conditions.
A population-based longitudinal study by dr. Hirvikoski uncovered excess premature death among people with ID. The increased risk for causes of death were potentially amendable to health care, including cause-specific mortality in circulatory system and neoplasm. Challenging behaviors, including aggression, destructive behavior, and self-harm, occur in an estimated 10-15% of patients with ID. Second-generation antipsychotics (SGAs) are now widely prescribed off-label to manage these behaviors. However, the long-term neurologic, metabolic, and hormonal effects of SGAs in this population remain largely unknown.
A pilot study by Nylander et al., suggest that a modified version of dialectic behavioral therapy is effective in reducing self-harm and can reduce the number of hospital admissions on an individual level. However, a larger cohort study assessing the ability for emotion regulation to reduce self-harm is warranted.
METHODS
Study design
The first part of the study (aim 1) has a cross-sectional design while the second part (aim 2) is an interventional trial.
Participants
Inclusion criteria:
ID Group: 40 individuals with mild ID (DSM-5 criteria, IQ 52-70) ASD Group: 40 individuals with ASD (DSM-5 criteria, IQ 85-115) TD Group: 80 individuals without neurodevelopmental disorders (IQ 85-115) All study participants are adults between the ages of 18-45, and can read and communicate in Swedish. The control group are matched by sex and age ± 5 years.
Exclusion criteria: Presence of severe sensory impairments (e.g., blindness, deafness); current psychosis or affective disorder; significant neurologic disorders (e.g., epilepsy) or degenerative disorder (e.g.. dementia, Parkinson's disease); ongoing substance abuse, specific medication that enhance cognitive performance (central stimulants) or psychotropic medication that could affect task performance (e.g., anti-epileptic medication, stimulants), emotion regulation therapy or corresponding psychotherapy during the last 12 months.
Procedure
Informed written consent will be obtained from all participants prior to inclusion. During the pre-assessment phase all study participants will undergo the following assessments (Mini-International Neuropsychiatric interview (M.I.N.I.), Wechsler Adult Intelligence Scale (WAIS-IV), Social Responsiveness scale (SRS-2), The Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) Interview Form).
All outcome measures from the emotion regulation therapy will be administered at baseline, post-treatment (primary endpoint), and at 6-month follow-up (except for client satisfaction questionnaire and negative effects questionnaire):
Difficulties in emotion regulation scale (DERS-SF), The Behavior Problems Inventory (BPI-01), World Health Organization Disability Assessment Schedule 2.0, The Clinical Global Impression - Severity (CGI-S) and Clinical Global Impression - Improvement (CGI-I) Scales, Client Satisfaction Questionnaire (CSQ-8), Caregiver Burden Inventory (CBI), Negative effects questionnaire (NEQ). In addition we will collect data on healthcare used by participants before and after treatment.
Testing protocol for psychological experiments with eye-tracking
Eye tracking technology offers a non-invasive and cost-effective method for studying cognitive processes and behavioral patterns in individuals with developmental disorders.
Emotion recognition task:
Design. The emotional recognition task will consist of a series of trials, each presenting a facial expression representing one of the basic emotions: happiness, sadness, anger, fear, surprise, and disgust. The face for each trial is chosen randomly. Each trial will begin with a fixation cross displayed at the center of the screen for 500 ms, followed by the presentation of a face, on either the left or right side, that changes from neutral to the emotion that the test subject is asked to identify.
Objective. Participants are asked to answer if the statement is correct by giving thumbs up for correct statement and thumbs down for incorrect statement.
Data collection. Reaction time (time taken to select an answer), and accuracy (correct identification of the emotion) will be recorded. Eye-tracking data consists of two parameters. Orientation toward eyes measured by the saccade gaze motion, and gaze path divided into areas of interest. Faces are divided into four regions of interest (whole face, eyes, nose and mouth).
Emotion reappraisal task:
Design. This task consists of two conditions: view and reappraise. During the view phase, participants are given the instruction to watch an image before the image is presented. Afterwards the participants are asked to rate how emotionally negative the image was on a Likert scale of 1-8. During the reappraisal phase, participants are given the instruction to reappraise before an image is presented. Participants are asked to state the cognitive reappraisal aloud. Afterwards the participants are asked to rate how emotionally negative the image was again on the Likert scale.
Objective. Participants are asked to watch the image in the view condition and instructed to change their emotional experience through cognitive reappraisal during the reappraisal condition. Expressing positive outcomes or alternative meanings that are less negative reflect their ability for reappraisal, and the decrease in negative emotion reflect their reappraisal efficacy.
Data collection. Baseline reactivity to images, reappraisal ability and efficacy will be registered. The reappraisal statements will be analyzed by a researcher blind to the study hypothesis. Pupil dilatation will be recorded for each trial.
Social reinforcement learning task:
Design. Two shapes with different orientations are presented for each trial. At the beginning of the trial a hidden rule for correct answer is established. Depending on how the test subject answers, a face depicting a positive or negative feedback is provided. When a certain number of correct answers are provided which reflect an understanding of the underlaying rule, the rule switches. The task is to identify the new rule.
Objective. Participants are asked to provide the correct answer and through social reinforced learning identify the underlaying rule.
Data collection. Reaction time (time to response) and accuracy (correct answers) will be recorded. Eye-tracking data consists of two main parameters. Pupilar dilatation and gaze path (length) will be measured during each trial.
Emotion regulation therapy
The psychotherapy for emotion regulation is an adapted version of the DBT skills Manual by Linehan for patients with ID. The text has been simplified, and illustrations have been added to facilitate learning. In addition, metaphors have been removed, making it more user-friendly for the targeted populations. DBT-SS was first pioneered by Julia Brown. A Swedish version of the treatment has been tested in a case study.
The adapted treatment consists of nine skill systems. The treatment consists of 24 sessions given both individually and in group sessions. The treatment will be provided by licensed psychologist. Health care provider or relatives who live with the participant are invited to facilitate learning and practicing the skills as well as aid them in responding to questionnaires.
Feasibility will be assessed according to the RE-AIM framework (reach, effectiveness, adoption, implementation, maintenance). Reach will be measured by looking at the percentage eligible/excluded, reasons for refusal or exclusion. Effectiveness will be measured using symptom reductions on the primary outcome measures (DERS-SF and WHODAS 2.0). Adoption will be assessed by looking at short-term attrition during the treatment, self-reported time spent on assignments, and the Client Satisfaction Questionnaire (CSQ-8) at post-treatment. Adverse events data will be collected post-treatment and at the 6-month follow-up where the patients will rate a list of common adverse events using the negative effects questionnaire (NEQ). Burden on caregivers will be assessed using Care Burden Inventory (CBI). Implementation will be assessed by looking at the number of additional telephone calls made by therapists. Lastly, total health care consumption will be compared six month before and six months after treatment (at one year follow up).
Fidelity in the treatment is ensured by thorough training and continuous supervision between sessions. After each session, the therapist must fill in a "Fidelity checklist" that outlines the specific elements that therapists need to cover in each session. Evaluation of treatment outcomes at post-treatment is performed by an independent researcher.
Data analysis plan
The investigator will employ machine learning algorithms using tidymodels to build predictive models, evaluating their performance through internal validation and area under the curve (AUC) metrics (Aim 1A). To evaluate whether emotion regulation therapy improves emotion processing in patients with ID (Aim 1B), the investigator will employ a repeated measures ANOVA or mixed-effects models to compare pre- and post-treatment performance on emotion recognition tasks, reappraisal tasks, and eye-tracking metrics. Effect sizes will be calculated using partial eta-squared (η²) for ANOVA or marginal R² for mixed-effects models.
To evaluate the efficacy of emotion regulation therapy for ID patients, the investigator will use mixed-effects linear regression models to compare pre- and post-treatment scores on DERS-SF and WHODAS 2.0, calculating within-group effect sizes using Cohen's d (Aim 2A). Feasibility will be analyzed according to the RE-AIM framework, examining metrics such as eligibility/exclusion percentages, attrition rates, time spent on assignments, CSQ-8 scores, adverse events, and additional support required during treatment (Aim 2B). Throughout the analysis, the investigator will ensure appropriate data transformations (e.g., log-transformation for reaction times) and alternative non-parametric tests when normality assumptions are not met.
Power calculation
Previous studies have demonstrated the effectiveness of cognitive behavioural therapy (CBT) and DBT-informed interventions for improving emotional regulation in individuals with ID, showing medium effect sizes (Cohen's d ranging from 0.3-0.6). Assuming an effect size of 0.5 and a standard deviation of 1 (0.8-1.1) for standardised effect size, an alpha level of 0.05, and 80% power, a conservative estimate would suggest that a sample size of approximately 30-35 participants is required to detect a significant improvement in DERS-SF. The investigator plan to recruit more participants than required for the primary analysis to account for missing or incomplete data and to ensure that the study maintains statistical power. This approach will also enable robust subgroup analyses and enhance the overall generalizability of the results.
- Being tested
- Emotion regulation
- Keywords
- Emotion regulation, Psychological experiment, Psychotherapy
- Medical subject headings
- Intellectual Disability, Autism Spectrum Disorder, Emotional Regulation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Emotion regulationBehavioural
The intervention is an adapted version of skills training that stems from DBT. The text has been simplified, and illustrations have been added to facilitate learning. It consists of nine skill-systems that are delivered during 24 weeks, one group session and individual therapy session per week. A licensed psychologist is responsible for each individual treatment. Care givers or relatives are given support and encouraged to participate and help the study participant to complete their homework assignments.
| Study group | Role | What they receive |
|---|---|---|
| Emotion regulation | Experimental | DBT-SS Receives: Behavioral: Emotion regulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difficulties in emotion regulation scale (DERS-SF)
DERS-SF is a self-report questionnaire that assesses individuals' difficulties in emotion regulation. It consists of 18 questions, rated on a Likert scale of 1-5, and takes 10 minutes to complete.
Total point: 18-90 Higher scores = greater emotion dysregulation
Measured: From enrollment to the end of treatment at 24 weeks
Secondary outcomes (7)
World Health Organization Disability Assessment Schedule 2.0
the interview-administered version is a comprehensive tool designed to assess disability and functioning across multiple domains in adults aged 18 and older. WHODAS 2.0 evaluates six key areas of functioning: cognition, mobility, self-care, getting alone, life activities, and participation. The interview-administered version is conducted by a trained interviewer who asks questions and records the respondent's answers. This format allows for clarification and ensures all items are addressed. It takes 20-30 minutes to complete.
Total point: Varies by version (e.g., 12- or 36-item), but scores are converted to a 0-100 metric Higher scores = greater disability
Measured: From enrollment to the end of treatment at 24 weeks
The Clinical Global Impression - Severity scale (CGI-S)
CGI-S will be used to assess overall clinical severity by the clinican. Total points: 1-7 Higher scores = more severe symptoms
Measured: From enrollment to the end of treatment at 24 weeks
Clinical Global Impression - Improvement scale (CGI-I)
will be used to assess treatment response by the clinician. Total points: 1-7 Higher scores = worsening symptoms or lack of improvement
Measured: From enrollment to the end of treatment at 24 weeks
Client Satisfaction Questionnaire (CSQ-8)
CSQ-8 evaluates client satisfaction with the intervention or treatment received. This self-report questionnaire takes approximately 5-10 minutes to complete and consists of 8 items rated on a Likert scale. It assesses various aspects of satisfaction, including the quality of service, helpfulness, and overall experience.
Total points: 8-32 Higher scores = greater satisfaction (lower scores indicate dissatisfaction)
Measured: From enrollment to the end of treatment at 24 weeks
The Behavior Problems Inventory (BPI-01)
The BPI-01 is an informant-based behavioral assessment tool used to evaluate maladaptive behaviors in individuals with intellectual and developmental disabilities, including autism spectrum disorders. The BPI-01 measures in detail the frequency and severity of three common types of problematic behaviors: self-injurious behavior, stereotyped behavior, and aggressive/destructive behavior. The instrument consists of 52 questions answered by an informant who knows the person well, typically a caregiver or family member. The BPI-01 takes approximately 15 minutes to complete and provides a comprehensive picture of behavioral problems in the individual.
Self-Injurious Behavior:
Frequency: 0-56 (14 items × 0-4) Severity: 14-42 (14 items × 1-3)
Stereotyped Behavior:
Frequency: 0-96 (24 items × 0-4) Severity: 24-72 (24 items × 1-3)
Aggressive/Destructive Behavior:
Frequency: 0-44 (11 items × 0-4) Severity: 11-33 (11 items × 1-3)
Higher scores = more frequent/severe problematic behaviors
Measured: From enrollment to the end of treatment at 24 weeks
Negative effects questionnaire (NEQ)
NEQ is a self-report instrument designed to assess adverse events associated with psychological treatments. It consists of 32-item and an open-ended question in the end. Participants rate items on a five-point Likert scale, with the questionnaire taking approximately 10-15 minutes to complete.
Total points: 20-80 Higher scores = greater negative treatment effects
Measured: From enrollment to the end of treatment at 24 weeks
Caregiver Burden Inventory
A scale for measuring caregiver burden that includes dimensions such as time demands, impact on relationships, and emotional effects.
Total items: 24 Response scale: 0-4 0 = Not at all descriptive
- = A little descriptive
- = Moderately descriptive
- = Very descriptive
- = Extremely descriptive Total score range: 0-96 Higher scores indicate greater caregiver burden.
Measured: From enrollment to the end of treatment at 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Mar 2025
- Study start15 Aug 2026 (estimated)
- Primary completion30 Sep 2028 (estimated)
- Study completion30 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (13)Papers the sponsor has linked to this study.
- Other trials for Intellectual Disabilities (F70-F79)Studies of the same condition, open and under way.
- More trials run by Karolinska InstitutetThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Karolinska Institutet
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Christian Rück, Karolinska Institutet
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06894264
- Sponsor's protocol ID
- EPRID
- Acronym
- EPRID
- Status last verified
- Mar 2026
- First submitted
- 10 Feb 2025
- Last updated
- 12 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: To avoid identification of individual study participants
Publications
Rosendahl-Santillo A, Lantto R, Nylander L, Thylander C, Schultz P, Brown J, Wallinius M, Westling S. Dialectical behavior therapy-skills system for cognitively challenged individuals with self-harm: a Swedish pilot study. Int J Dev Disabil. 2021 Sep 1;69(4):533-545. doi: 10.1080/20473869.2021.1965825. eCollection 2023.
PubMed 37346252Brown JF, Brown MZ, Dibiasio P. Treating Individuals With Intellectual Disabilities and Challenging Behaviors With Adapted Dialectical Behavior Therapy. J Ment Health Res Intellect Disabil. 2013 Oct;6(4):280-303. doi: 10.1080/19315864.2012.700684.
PubMed 23914278Linehan MM, Wilks CR. The Course and Evolution of Dialectical Behavior Therapy. Am J Psychother. 2015;69(2):97-110. doi: 10.1176/appi.psychotherapy.2015.69.2.97.
PubMed 26160617Jahoda A, Dagnan D, Hastings R, Gillooly A, Miller J, Baines S, Hatton C. Adapting psychological interventions for people with severe and profound intellectual disabilities: A behavioural activation exemplar. J Appl Res Intellect Disabil. 2024 Mar;37(2):e13199. doi: 10.1111/jar.13199.
PubMed 38361369Campos-Jara R, Martinez-Salazar C, Campos-Jara C, Fernandez JM, Martinez-Garcia D, Contreras-Osorio F. Pharmacological treatment for challenging behavior in adults with intellectual disability: Systematic review and meta-analysis. Span J Psychiatry Ment Health. 2024 Oct-Dec;17(4):231-238. doi: 10.1016/j.rpsm.2023.01.003. Epub 2023 Jan 31.
PubMed 37839961Kleberg JL, Willfors C, Bjorlin Avdic H, Riby D, Galazka MA, Guath M, Nordgren A, Strannegard C. Social feedback enhances learning in Williams syndrome. Sci Rep. 2023 Jan 4;13(1):164. doi: 10.1038/s41598-022-26055-8.
PubMed 36599864Garrison J, Erdeniz B, Done J. Prediction error in reinforcement learning: a meta-analysis of neuroimaging studies. Neurosci Biobehav Rev. 2013 Aug;37(7):1297-310. doi: 10.1016/j.neubiorev.2013.03.023. Epub 2013 Apr 6.
PubMed 23567522Subramanian A, Chitlangia S, Baths V. Reinforcement learning and its connections with neuroscience and psychology. Neural Netw. 2022 Jan;145:271-287. doi: 10.1016/j.neunet.2021.10.003. Epub 2021 Oct 22.
PubMed 34781215Littlewood M, Dagnan D, Rodgers J. Exploring the emotion regulation strategies used by adults with intellectual disabilities. Int J Dev Disabil. 2018 Jun 8;64(3):204-211. doi: 10.1080/20473869.2018.1466510.
PubMed 34141307Samson AC, Sokhn N, Van Herwegen J, Dukes D. An exploratory study on emotion regulation strategy use in individuals with Williams syndrome, autism spectrum disorder and intellectual disability. Front Psychiatry. 2022 Nov 23;13:940872. doi: 10.3389/fpsyt.2022.940872. eCollection 2022.
PubMed 36506439Jenner LA, Farran EK, Welham A, Jones C, Moss J. The use of eye-tracking technology as a tool to evaluate social cognition in people with an intellectual disability: a systematic review and meta-analysis. J Neurodev Disord. 2023 Dec 4;15(1):42. doi: 10.1186/s11689-023-09506-9.
PubMed 38044457Scotland JL, McKenzie K, Cossar J, Murray A, Michie A. Recognition of facial expressions of emotion by adults with intellectual disability: Is there evidence for the emotion specificity hypothesis? Res Dev Disabil. 2016 Jan;48:69-78. doi: 10.1016/j.ridd.2015.10.018. Epub 2015 Nov 5.
PubMed 26546741Hermann H, Berndt N, Lytochkin A, Sappok T. Behavioural phenomena in persons with an intellectual developmental disorder according to the level of emotional development. J Intellect Disabil Res. 2022 May;66(5):483-498. doi: 10.1111/jir.12930. Epub 2022 Mar 31.
PubMed 35357054
Study at a glance
From the registry record, last updated by the sponsor on 12 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Emotion Processing and Regulation in People With Intellectual Disability
- ClinicalTrials.gov ID
- NCT06894264
- Acronym / sponsor ID
- EPRID / EPRID
- Keywords
- Emotion regulation, Psychological experiment, Psychotherapy
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Karolinska InstitutetUniversity, hospital or other
- Study start
- 15 Aug 2026 (estimated)
- Primary completion
- 30 Sep 2028 (estimated)
- Study completion
- 30 Dec 2028 (estimated)
- First posted
- 25 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
BACKGROUND
Intellectual disability (ID) is neurodevelopmental disorder with social impairments, in areas such as interpersonal communication skills and emotion regulation. This overlaps with disabilities associated with autism spectrum disorder (ASD). Differences in emotion processing, specifically emotion recognition, reappraisal, and reinforcement learning, has not been compared between patients with ID and ASD. Despite difficulties in emotion regulation among patients with ID, there is a lack of adapted psychotherapy for this patient group.
AIMS
- To examine differences in emotion processing in individuals with intellectual disability (ID) compared to individuals with autism spectrum disorder (ASD) and typically developed individuals.
- To evaluate the feasibility and effectiveness of an adapted psychotherapeutic intervention to improve emotion regulation in individuals with ID.
Data and method
The first research question is addressed through a cross-sectional study involving 160 participants: 40 individuals with ID, 40 individuals with ASD, and 80 typically developed controls. Participants will undergo psychological experiments where the investigator simultaneously measure eye movement and pupil dilation using an eye-tracker. To investigate different aspects of social cognition, the investigator will use three psychological experiments: emotion recognition, emotion reappraisal, and reinforced learning in a social context. Differences in social cognition are subsequently used in predictive models to predict the group affiliation of study participants.
To evaluate the effectiveness and feasibility of an adapted emotion regulation treatment based on Dialectic Behavioral Therapy skills system (DBT-SS), the 40 study participants with ID will undergo a manual-based psychotherapy. The treatment consists of 24 group and individual sessions over 24 weeks. The treatment includes nine skill-systems. Outcome measures are administered at baseline, post-treatment, and at a 6-month follow-up.
SOCIETAL RELENVANCE
This research addresses a significant knowledge gap in social cognition and mental health in individuals with ID. The results may lead to a better understanding of differences in social cognition compared to individuals with ASD, and effective, targeted interventions for emotion regulation in individuals with ID. In the long run, the treatment could help reduce off-label prescription of antipsychotics to manage behavioral deviations in individuals with ID, as challenging behaviors often stem from difficulties with emotion regulation.
PROJECT REALISATION
The research group consists of an interdisciplinary composition of experts in neuropsychology, experimental psychology, and implementation of psychotherapeutic research. The project has obtained ethical approval and follows the principles of open science, with pre-registration of study protocols.
Detailed description
BACKGROUND
Individuals with intellectual disability (ID) experience significant difficulties in interpreting, controlling, and expressing emotions. These deficits in emotion processing contribute to challenging behaviors, manifesting as aggressive outbursts, self-injurious behaviors, or withdrawal. The ability to understand and regulate emotions plays a vital role in daily functioning and social interactions. Impairment in emotion regulation also leads to increased stress, anxiety, and mood disorders, further exacerbating behavioral issues and negatively impacting the overall quality of life for individuals with ID.
Traditional cognitive tests (e.g., Wechsler Adult Intelligence Scale, WAIS) are reliable in measuring certain cognitive abilities but fall short in assessing emotional processes and social learning under uncertainty. New, objective measurement tools grounded in cognitive and neuroscience theories, would enhance our understanding of the challenges that patients with ID face in a social context.
Study has shown that Patients with ID have greater difficulty recognizing emotions compared to typically developing peers. Patients with ASD share the same functional impairment. However, the underlying mechanisms for these difficulties may differ between the two groups. For individuals with ASD, reduced fixation on the eye region has been proposed as a contributing factor to their emotion recognition difficulties, while the difficulties for individuals with ID may be due to more complex cognitive factors beyond simply reduced eye fixation.
Emotional reappraisal is a cognitive strategy used to regulate emotions by reinterpreting the meaning of emotional stimuli. It is crucial for effective emotion regulation as it allows individuals to change their emotional responses by altering their perspective on the emotional situations. For individuals with ID, the cognitive demands of reappraisal may be challenging due to limitations in executive functioning and abstract thinking, whereas for ASD, difficulties in theory of mind could impede the ability to reframe emotional situations effectively. Elucidating the exact impairment in emotion reappraisal could therefore impact assessment tools, treatment strategy and response to emotion regulation therapy.
Research in psychology and neuroscience has identified feedback learning as a crucial form of learning in humans. Typically, people adhere to a simple, yet powerful and flexible strategy called reinforcement learning (RL). Central to RL is that learning is driven by a mismatch between the initial belief about the outcome and the actual outcome. This mismatch is known as a prediction error. Differences in how prediction errors are computed and used for learning could be a distinct feature in cognitive processing between patients with ID and ASD. Moreover, understanding prediction errors and reinforcement learning mechanisms from a social context may be crucial in explaining how individuals assimilate and respond to clinical interventions, potentially offering insights into treatment efficacy and personalized therapeutic approaches.
Prevalence of challenging behavior in individuals with ID is between 10-15% and a common reason for refferal to psychiatry. 65% of youths with intellectual and developmental disabilities who were referred to a mental health service were prescribed antipsychotics. However, randomized controlled trials have not demonstrated consistent efficacy for this approach (SMD=-0.85; 95% CI=-1.69 to -0.01; p=0.05). Despite the clear need for psychological interventions to adress this issue, there is a striking disparity in the availability and application of psychotherapy for individuals with ID compared to the general population. This gap in treatment options highlights the necessity for targeted interventions that enhance emotion regulation and social functioning in this population. Among the various therapeutic approaches, skills-based training programs rooted in Dialectical Behavior Therapy (DBT) have shown promise in addressing these challenges. DBT focuses on teaching skills in mindfulness, distress tolerance, emotion regulation, and interpersonal effectiveness. In a pilot study with six participants, this form of treatment led to decreased challenging behaviors, improved global functioning, and reduced hospital admissions, suggesting potential efficacy of this treatment approach in a Swedish context. However, existing studies have typically involved small numbers of participants, highlighting the need for further research to elucidate the efficacy and feasibility of emotion regulation therapy for patients with ID. Despite these limitations, DBT-SS represents a promising avenue for improving the quality of life and social functioning of individuals with intellectual disabilities.
Preliminary results
Associate Professor Kleberg's research group has extensive experience conducting eye-tracking studies in individuals with Autism Spectrum Disorder (ASD) and rare genetic syndromes across varying cognitive abilities. Their previous research has revealed distinct eye-movement patterns and pupillary responses in individuals with rare genetic syndromes, such as Williams syndrome and Turner syndrome, which differ from those observed in individuals with ASD during psychological experiments. This line of research is crucial for understanding the unique cognitive and social profiles associated with different neurodevelopmental conditions.
A population-based longitudinal study by dr. Hirvikoski uncovered excess premature death among people with ID. The increased risk for causes of death were potentially amendable to health care, including cause-specific mortality in circulatory system and neoplasm. Challenging behaviors, including aggression, destructive behavior, and self-harm, occur in an estimated 10-15% of patients with ID. Second-generation antipsychotics (SGAs) are now widely prescribed off-label to manage these behaviors. However, the long-term neurologic, metabolic, and hormonal effects of SGAs in this population remain largely unknown.
A pilot study by Nylander et al., suggest that a modified version of dialectic behavioral therapy is effective in reducing self-harm and can reduce the number of hospital admissions on an individual level. However, a larger cohort study assessing the ability for emotion regulation to reduce self-harm is warranted.
METHODS
Study design
The first part of the study (aim 1) has a cross-sectional design while the second part (aim 2) is an interventional trial.
Participants
Inclusion criteria:
ID Group: 40 individuals with mild ID (DSM-5 criteria, IQ 52-70) ASD Group: 40 individuals with ASD (DSM-5 criteria, IQ 85-115) TD Group: 80 individuals without neurodevelopmental disorders (IQ 85-115) All study participants are adults between the ages of 18-45, and can read and communicate in Swedish. The control group are matched by sex and age ± 5 years.
Exclusion criteria: Presence of severe sensory impairments (e.g., blindness, deafness); current psychosis or affective disorder; significant neurologic disorders (e.g., epilepsy) or degenerative disorder (e.g.. dementia, Parkinson's disease); ongoing substance abuse, specific medication that enhance cognitive performance (central stimulants) or psychotropic medication that could affect task performance (e.g., anti-epileptic medication, stimulants), emotion regulation therapy or corresponding psychotherapy during the last 12 months.
Procedure
Informed written consent will be obtained from all participants prior to inclusion. During the pre-assessment phase all study participants will undergo the following assessments (Mini-International Neuropsychiatric interview (M.I.N.I.), Wechsler Adult Intelligence Scale (WAIS-IV), Social Responsiveness scale (SRS-2), The Vineland Adaptive Behavior Scales, Third Edition (Vineland-3) Interview Form).
All outcome measures from the emotion regulation therapy will be administered at baseline, post-treatment (primary endpoint), and at 6-month follow-up (except for client satisfaction questionnaire and negative effects questionnaire):
Difficulties in emotion regulation scale (DERS-SF), The Behavior Problems Inventory (BPI-01), World Health Organization Disability Assessment Schedule 2.0, The Clinical Global Impression - Severity (CGI-S) and Clinical Global Impression - Improvement (CGI-I) Scales, Client Satisfaction Questionnaire (CSQ-8), Caregiver Burden Inventory (CBI), Negative effects questionnaire (NEQ). In addition we will collect data on healthcare used by participants before and after treatment.
Testing protocol for psychological experiments with eye-tracking
Eye tracking technology offers a non-invasive and cost-effective method for studying cognitive processes and behavioral patterns in individuals with developmental disorders.
Emotion recognition task:
Design. The emotional recognition task will consist of a series of trials, each presenting a facial expression representing one of the basic emotions: happiness, sadness, anger, fear, surprise, and disgust. The face for each trial is chosen randomly. Each trial will begin with a fixation cross displayed at the center of the screen for 500 ms, followed by the presentation of a face, on either the left or right side, that changes from neutral to the emotion that the test subject is asked to identify.
Objective. Participants are asked to answer if the statement is correct by giving thumbs up for correct statement and thumbs down for incorrect statement.
Data collection. Reaction time (time taken to select an answer), and accuracy (correct identification of the emotion) will be recorded. Eye-tracking data consists of two parameters. Orientation toward eyes measured by the saccade gaze motion, and gaze path divided into areas of interest. Faces are divided into four regions of interest (whole face, eyes, nose and mouth).
Emotion reappraisal task:
Design. This task consists of two conditions: view and reappraise. During the view phase, participants are given the instruction to watch an image before the image is presented. Afterwards the participants are asked to rate how emotionally negative the image was on a Likert scale of 1-8. During the reappraisal phase, participants are given the instruction to reappraise before an image is presented. Participants are asked to state the cognitive reappraisal aloud. Afterwards the participants are asked to rate how emotionally negative the image was again on the Likert scale.
Objective. Participants are asked to watch the image in the view condition and instructed to change their emotional experience through cognitive reappraisal during the reappraisal condition. Expressing positive outcomes or alternative meanings that are less negative reflect their ability for reappraisal, and the decrease in negative emotion reflect their reappraisal efficacy.
Data collection. Baseline reactivity to images, reappraisal ability and efficacy will be registered. The reappraisal statements will be analyzed by a researcher blind to the study hypothesis. Pupil dilatation will be recorded for each trial.
Social reinforcement learning task:
Design. Two shapes with different orientations are presented for each trial. At the beginning of the trial a hidden rule for correct answer is established. Depending on how the test subject answers, a face depicting a positive or negative feedback is provided. When a certain number of correct answers are provided which reflect an understanding of the underlaying rule, the rule switches. The task is to identify the new rule.
Objective. Participants are asked to provide the correct answer and through social reinforced learning identify the underlaying rule.
Data collection. Reaction time (time to response) and accuracy (correct answers) will be recorded. Eye-tracking data consists of two main parameters. Pupilar dilatation and gaze path (length) will be measured during each trial.
Emotion regulation therapy
The psychotherapy for emotion regulation is an adapted version of the DBT skills Manual by Linehan for patients with ID. The text has been simplified, and illustrations have been added to facilitate learning. In addition, metaphors have been removed, making it more user-friendly for the targeted populations. DBT-SS was first pioneered by Julia Brown. A Swedish version of the treatment has been tested in a case study.
The adapted treatment consists of nine skill systems. The treatment consists of 24 sessions given both individually and in group sessions. The treatment will be provided by licensed psychologist. Health care provider or relatives who live with the participant are invited to facilitate learning and practicing the skills as well as aid them in responding to questionnaires.
Feasibility will be assessed according to the RE-AIM framework (reach, effectiveness, adoption, implementation, maintenance). Reach will be measured by looking at the percentage eligible/excluded, reasons for refusal or exclusion. Effectiveness will be measured using symptom reductions on the primary outcome measures (DERS-SF and WHODAS 2.0). Adoption will be assessed by looking at short-term attrition during the treatment, self-reported time spent on assignments, and the Client Satisfaction Questionnaire (CSQ-8) at post-treatment. Adverse events data will be collected post-treatment and at the 6-month follow-up where the patients will rate a list of common adverse events using the negative effects questionnaire (NEQ). Burden on caregivers will be assessed using Care Burden Inventory (CBI). Implementation will be assessed by looking at the number of additional telephone calls made by therapists. Lastly, total health care consumption will be compared six month before and six months after treatment (at one year follow up).
Fidelity in the treatment is ensured by thorough training and continuous supervision between sessions. After each session, the therapist must fill in a "Fidelity checklist" that outlines the specific elements that therapists need to cover in each session. Evaluation of treatment outcomes at post-treatment is performed by an independent researcher.
Data analysis plan
The investigator will employ machine learning algorithms using tidymodels to build predictive models, evaluating their performance through internal validation and area under the curve (AUC) metrics (Aim 1A). To evaluate whether emotion regulation therapy improves emotion processing in patients with ID (Aim 1B), the investigator will employ a repeated measures ANOVA or mixed-effects models to compare pre- and post-treatment performance on emotion recognition tasks, reappraisal tasks, and eye-tracking metrics. Effect sizes will be calculated using partial eta-squared (η²) for ANOVA or marginal R² for mixed-effects models.
To evaluate the efficacy of emotion regulation therapy for ID patients, the investigator will use mixed-effects linear regression models to compare pre- and post-treatment scores on DERS-SF and WHODAS 2.0, calculating within-group effect sizes using Cohen's d (Aim 2A). Feasibility will be analyzed according to the RE-AIM framework, examining metrics such as eligibility/exclusion percentages, attrition rates, time spent on assignments, CSQ-8 scores, adverse events, and additional support required during treatment (Aim 2B). Throughout the analysis, the investigator will ensure appropriate data transformations (e.g., log-transformation for reaction times) and alternative non-parametric tests when normality assumptions are not met.
Power calculation
Previous studies have demonstrated the effectiveness of cognitive behavioural therapy (CBT) and DBT-informed interventions for improving emotional regulation in individuals with ID, showing medium effect sizes (Cohen's d ranging from 0.3-0.6). Assuming an effect size of 0.5 and a standard deviation of 1 (0.8-1.1) for standardised effect size, an alpha level of 0.05, and 80% power, a conservative estimate would suggest that a sample size of approximately 30-35 participants is required to detect a significant improvement in DERS-SF. The investigator plan to recruit more participants than required for the primary analysis to account for missing or incomplete data and to ensure that the study maintains statistical power. This approach will also enable robust subgroup analyses and enhance the overall generalizability of the results.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Emotion regulation | Experimental | Behavioral: Emotion regulationDBT-SS |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Clinically diagnosed with mild ID based on DSM-5 criteria, corresponding to a general IQ between 52-70.
- Can read and communicate in Swedish.
Key exclusion criteria (5 listed)
- Presence of severe sensory impairments (e.g., blindness, deafness)
- Current psychosis or affective disorder; significant neurologic disorders (e.g., epilepsy) or degenerative disorder (e.g.., dementia, Parkinson's disease)
- Ongoing substance abuse
- Specific medication that enhance cognitive performance (central stimulants) or psychotropic medication that could affect task performance (anti-epileptic medication)
- Emotion regulation therapy or corresponding psychotherapy last 12 months.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Emotion regulationThe intervention is an adapted version of skills training that stems from DBT. The text has been simplified, and illustrations have been added to facilitate learning. It consists of nine skill-systems that are delivered during 24 weeks, one group session and individual therapy session per week. A licensed psychologist is responsible for each individual treatment. Care givers or relatives are given support and encouraged to participate and help the study participant to complete their homework assignments. | Behavioural | Emotion regulation |
Primary outcome
Difficulties in emotion regulation scale (DERS-SF)
Time frame: From enrollment to the end of treatment at 24 weeks
DERS-SF is a self-report questionnaire that assesses individuals' difficulties in emotion regulation. It consists of 18 questions, rated on a Likert scale of 1-5, and takes 10 minutes to complete. Total point: 18-90 Higher scores = greater emotion dysregulation
7 secondary outcomes
World Health Organization Disability Assessment Schedule 2.0
Time frame: From enrollment to the end of treatment at 24 weeks
The Clinical Global Impression - Severity scale (CGI-S)
Time frame: From enrollment to the end of treatment at 24 weeks
Clinical Global Impression - Improvement scale (CGI-I)
Time frame: From enrollment to the end of treatment at 24 weeks
Client Satisfaction Questionnaire (CSQ-8)
Time frame: From enrollment to the end of treatment at 24 weeks
The Behavior Problems Inventory (BPI-01)
Time frame: From enrollment to the end of treatment at 24 weeks
Negative effects questionnaire (NEQ)
Time frame: From enrollment to the end of treatment at 24 weeks
Caregiver Burden Inventory
Time frame: From enrollment to the end of treatment at 24 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Mar 2026.
- Background: PubMed 37346252Rosendahl-Santillo A, Lantto R, Nylander L, Thylander C, Schultz P, Brown J, Wallinius M, Westling S. Dialectical behavior therapy-skills system for cognitively challenged individuals with self-harm: a Swedish pilot study. Int J Dev Disabil. 2021 Sep 1;69(4):533-545. doi: 10.1080/20473869.2021.1965825. eCollection 2023.
- Background: PubMed 23914278Brown JF, Brown MZ, Dibiasio P. Treating Individuals With Intellectual Disabilities and Challenging Behaviors With Adapted Dialectical Behavior Therapy. J Ment Health Res Intellect Disabil. 2013 Oct;6(4):280-303. doi: 10.1080/19315864.2012.700684.
- Background: PubMed 26160617Linehan MM, Wilks CR. The Course and Evolution of Dialectical Behavior Therapy. Am J Psychother. 2015;69(2):97-110. doi: 10.1176/appi.psychotherapy.2015.69.2.97.
- Background: PubMed 38361369Jahoda A, Dagnan D, Hastings R, Gillooly A, Miller J, Baines S, Hatton C. Adapting psychological interventions for people with severe and profound intellectual disabilities: A behavioural activation exemplar. J Appl Res Intellect Disabil. 2024 Mar;37(2):e13199. doi: 10.1111/jar.13199.
- Background: PubMed 37839961Campos-Jara R, Martinez-Salazar C, Campos-Jara C, Fernandez JM, Martinez-Garcia D, Contreras-Osorio F. Pharmacological treatment for challenging behavior in adults with intellectual disability: Systematic review and meta-analysis. Span J Psychiatry Ment Health. 2024 Oct-Dec;17(4):231-238. doi: 10.1016/j.rpsm.2023.01.003. Epub 2023 Jan 31.
- Background: PubMed 36599864Kleberg JL, Willfors C, Bjorlin Avdic H, Riby D, Galazka MA, Guath M, Nordgren A, Strannegard C. Social feedback enhances learning in Williams syndrome. Sci Rep. 2023 Jan 4;13(1):164. doi: 10.1038/s41598-022-26055-8.
- Background: PubMed 23567522Garrison J, Erdeniz B, Done J. Prediction error in reinforcement learning: a meta-analysis of neuroimaging studies. Neurosci Biobehav Rev. 2013 Aug;37(7):1297-310. doi: 10.1016/j.neubiorev.2013.03.023. Epub 2013 Apr 6.
- Background: PubMed 34781215Subramanian A, Chitlangia S, Baths V. Reinforcement learning and its connections with neuroscience and psychology. Neural Netw. 2022 Jan;145:271-287. doi: 10.1016/j.neunet.2021.10.003. Epub 2021 Oct 22.
- Background: PubMed 34141307Littlewood M, Dagnan D, Rodgers J. Exploring the emotion regulation strategies used by adults with intellectual disabilities. Int J Dev Disabil. 2018 Jun 8;64(3):204-211. doi: 10.1080/20473869.2018.1466510.
- Background: PubMed 36506439Samson AC, Sokhn N, Van Herwegen J, Dukes D. An exploratory study on emotion regulation strategy use in individuals with Williams syndrome, autism spectrum disorder and intellectual disability. Front Psychiatry. 2022 Nov 23;13:940872. doi: 10.3389/fpsyt.2022.940872. eCollection 2022.
- Background: PubMed 38044457Jenner LA, Farran EK, Welham A, Jones C, Moss J. The use of eye-tracking technology as a tool to evaluate social cognition in people with an intellectual disability: a systematic review and meta-analysis. J Neurodev Disord. 2023 Dec 4;15(1):42. doi: 10.1186/s11689-023-09506-9.
- Background: PubMed 26546741Scotland JL, McKenzie K, Cossar J, Murray A, Michie A. Recognition of facial expressions of emotion by adults with intellectual disability: Is there evidence for the emotion specificity hypothesis? Res Dev Disabil. 2016 Jan;48:69-78. doi: 10.1016/j.ridd.2015.10.018. Epub 2015 Nov 5.
- Individual participant dataSharing planned: No. To avoid identification of individual study participants
Related trials for Intellectual Disabilities (F70-F79)
RecruitingObservational study
Falls In Spanish People With Intellectual Disabilities: Risk Factors And Predictive Equation. Falls.Di Study
Falls, Intellectual Disabilities (F70-F79)
Recruiting
Smart Inhaler and Remote Asthma Management in Adolescents With Intellectual and Developmental Disabilities
Asthma in Children, Intellectual Disabilities (F70-F79)
Not yet recruiting
A Single-Arm Interventional Trial of Pepper- Robot Delivered Cancer Education for Adults With Intellectual Disability
Cancer Awareness and Prevention Education, Breast Cancer Awareness
Recruiting
Optimizing Dimensions of Reinforcement
Intellectual Disabilities (F70-F79), Autism
Recruiting
Using Technologies to Promote HEalthy Lifestyles in Adolescents With Intellectual Disabilities
Intellectual Disabilities (F70-F79), Down Syndrome (DS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Emotion regulation in people with Intellectual Disabilities (F70-F79) and Autism Spectrum Disorder, run by Karolinska Institutet.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 12 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Long-Long Chen postdoctoral student, MD PhD (+46 0725670088, long.chen@ki.se), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difficulties in emotion regulation scale (DERS-SF) (time frame: From enrollment to the end of treatment at 24 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06894264, which also lists 13 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2026.